ArticleGene therapy2007
Downregulation of human CD46 by adenovirus serotype 35 vectors.
Article in Gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Adenovirus vector-mediated delivery of the CRISPR-CasRx system enables gene knockdown with suppressed collateral activity.Molecular therapy. Nucleic acids · 2026Article
- Adenovirus entry: Stability, uncoating, and nuclear import.Molecular microbiology · 2022Review
- Safe and efficientMolecular therapy. Methods & clinical development · 2022Article
- Human Species D Adenoviruses Isolated from Diarrheal Feces Show Low Infection Rates in Primary Nasal Epithelial Cells.Children (Basel, Switzerland) · 2021Article
- Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35.Molecular therapy oncolytics · 2021Article
- Glycomics and Proteomics Approaches to Investigate Early Adenovirus-Host Cell Interactions.Journal of molecular biology · 2018Review
- Efficient detection of human circulating tumor cells without significant production of false-positive cells by a novel conditionally replicating adenovirus.Molecular therapy. Methods & clinical development · 2016Article
- Attenuation of CD4+ T-cell function by human adenovirus type 35 is mediated by the knob protein.The Journal of general virology · 2012Article
- CD46 measles virus receptor polymorphisms influence receptor protein expression and primary measles vaccine responses in naive Australian children.Clinical and vaccine immunology : CVI · 2012Article
- CD46 processing: a means of expression.Immunobiology · 2012Review
- CD46 in innate and adaptive immunity: an update.Clinical and experimental immunology · 2011Review
- Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- CD46 plasticity and its inflammatory bias in multiple sclerosis.Archivum immunologiae et therapiae experimentalis · 2011Review
- Structure of the extracellular portion of CD46 provides insights into its interactions with complement proteins and pathogens.PLoS pathogens · 2010Article
- Presenilin/gamma-secretase cleaves CD46 in response to Neisseria infection.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Article
- In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46.Journal of virology · 2008Article
- CD46 Contributes to the severity of group A streptococcal infection.Infection and immunity · 2008Article
- Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses.Journal of immunology (Baltimore, Md. : 1950) · 2007Article
- Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3.Journal of immunotherapy (Hagerstown, Md. : 1997)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human CD46 (membrane cofactor protein), which serves as a receptor for a variety of pathogens, including strains of measles virus, human herpesvirus type 6 and Neisseria, is rapidly downregulated from the cell surface following infection by these pathogens. Here, we report that replication-incompetent adenovirus (Ad) serotype 35 (Ad35) vectors, which belong to subgroup B and recognize human CD46 as a receptor, downregulate CD46 following infection. A decline in the surface expression of CD46 in human peripheral blood mononuclear cells was detectable 6 h after infection, and reached maximum (72%) 12 h after infection. Ad35 vector-induced downregulation of surface CD46 levels gradually recovered after the removal of Ad35 vectors, however, complete recovery of CD46 expression was not observed even at 96 h after removal. The surface expression of CD46 was also reduced after incubation with fiber-substituted Ad serotype 5 (Ad5) vectors bearing Ad35 fiber proteins, ultraviolet-irradiated Ad35, vectors and recombinant Ad35 fiber knob proteins; in contrast, conventional Ad5 vectors did not induce surface CD46 downregulation, suggesting that the fiber knob protein of Ad35 plays a crucial role in the downregulation of surface CD46 density. These results have important implications for gene therapy using CD46-utilizing Ad vectors and for the pathogenesis of Ads that interact with CD46.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.